Between 2019 and 2023, prescriptions for nasal spray formulations increased from 4% to 48%, those for glucagon autoinjectors increased by 18%, and those for unmixed syringes dipped from 96% to 31% ...
Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback